Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1FED 1

Study Type

Interventional 1

Sponsor

Conditions

Spondylitis, Ankylosing 1Psoriasis 1Crohn Disease 1Arthritis, Rheumatoid 1Arthritis, Psoriatic 1Arthritis 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Has results × Herpes Zoster Vaccine × Clear all
NCT02538341 2021-11-23

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

University of Alabama at Birmingham

Phase 2 Completed
617 enrolled 17 charts

Arthritis, Arthritis, Rheumatoid, Crohn Disease, Psoriasis, Spondylitis, Ankylosing, Arthritis, Psoriatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡